Carlos Zayas Torres, MD
Cardiovascular Disease · Humacao, PRNPI 1740275429
Payments from drug & device makers
What this record shows
This record is dominated by gifts: $2,868 of the $4,454 with a category attached, or 64.4%. AbbVie accounts for 64.4% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2019 at $2,973 and has fallen 89.2% since, to $320 in 2025.
Across 55 payments — averaging $80.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Abbott$440
- Boehringer Ingelheim$191
- Amarin Pharma, Inc.$119
- Novartis$97
- AstraZeneca$90
- plus $650 from 14 others
Across 12 payments — averaging $1253.82 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$15K
What the payments were for
- Food & beverage$1,58636%
- Gifts$2,86864%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 1 | $2,868 |
| Abbott | 6 | $440 |
| Boehringer Ingelheim | 8 | $191 |
| Amarin Pharma, Inc. | 3 | $119 |
| Novartis | 5 | $97 |
| AstraZeneca | 5 | $90 |
| Kestra Medical Technology Services, Inc. | 1 | $83 |
| E.r. Squibb & Sons, L.L.C. | 4 | $82 |
| Pfizer | 4 | $80 |
| Amgen | 5 | $77 |
| Alnylam Pharmaceuticals Inc. | 2 | $63 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $47 |
| Johnson & Johnson | 2 | $46 |
| Bayer | 1 | $30 |
| Scpharmaceuticals Inc. | 1 | $30 |
| Cvrx, Inc. | 1 | $28 |
| Sanofi-aventis U.S. LLC | 1 | $27 |
| Novo Nordisk | 1 | $24 |
| GSK | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AVEIR$240
How this compares
$4,454 in reported general payments places this provider in the 60th percentile of 267 cardiovascular disease providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 256 | $277,434 |
| EntrestoSacubitril/Valsartan | 77 | $106,578 |
| Repatha SureclickEvolocumab | 85 | $92,695 |
| FarxigaDapagliflozin Propanediol | 61 | $83,314 |
| JardianceEmpagliflozin | 72 | $71,403 |
| MultaqDronedarone Hcl | 29 | $34,399 |
| XareltoRivaroxaban | 23 | $25,617 |
| BrilintaTicagrelor | 13 | $12,651 |
| VascepaIcosapent Ethyl | 14 | $6,656 |
| Olmesartan-Amlodipine-HctzOlmesartan/Amlodipin/Hcthiazid | 48 | $5,084 |
| Olmesartan Medoxomil | 287 | $5,008 |
| Metoprolol Succinate | 334 | $4,596 |
| Ezetimibe | 230 | $4,437 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 30 | $4,309 |
| Atorvastatin Calcium | 464 | $4,265 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $80 | $277,434256 claims |
| NovartisEntresto | $97 | $106,57877 claims |
| AstraZenecaFarxiga, Brilinta | $90 | $95,96574 claims |
| Boehringer IngelheimJardiance | $191 | $71,40372 claims |
| Sanofi-aventis U.S. LLCMultaq | $27 | $34,39929 claims |
| Johnson & JohnsonXarelto | $46 | $25,61723 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 267 cardiovascular disease providers in Puerto Rico.
Other cardiovascular disease in Humacao
- Maria Rios BonillaHumacao$12K
- Karen Rodriguez MaldonadoMayaguez$231K
- Jose NovoaBayamon$209K
- Manuel GuzmanSan Juan$203K
- Luis Rosado CarrilloGuaynabo$173K
- Jorge GonzalezCaguas$114K
- Luis GelyCaguas$89K
- Luis Renta RosaCarolina$83K
- Ramon PereaSan Juan$68K
- Denis Ruiz SerranoGuaynabo$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.